Dendreon Completes Submission of Biologics License Application fo...(new class of active cellular immunothera...)

Date:11/2/2009

new class of active cellular immunotherapies (ACIs) specifically designed to engage the patient's own immune system against cancer. PROVENGE and other ACIs are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer.

About Prostate Cancer

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer. An estimated 192,280 new cases are expected to be diagnosed in 2009. Approximately 27,360 men are expected to die this year from the disease.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including the FDA's actions with respect to the BLA and whether the FDA determines to convene an advisory committee to review the BLA; progre
'/>"/>

SOURCE Dendreon Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
3. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
4. Dendreon Reports Second Quarter 2009 Financial Results
5. Dendreon Signs Lease for New Manufacturing Facility in Atlanta
6. Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
9. Dendreon Announces Closing of Common Stock Offering
10. Dendreon Announces Common Stock Offering
11. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences